Esperion (NASDAQ:ESPR) is a small company developing a cholesterol drug with the aim to succeed Lipitor or at least to complement it. It is facing up to pharma giants like Sanofi, Amgen and Pfizer. But the company has one asset that nobody else does: its executive chairman is the one and only Roger Newton, an icon of the cholesterol business.
In September Esperion announced positive top-line results from a Phase 2a study of its drug, ETC-1002 when added to statin therapy in patients with elevated levels of low density LDL-C or "bad cholesterol".
Later in 2013 Esperion is planning a larger Phase 2b trial targeting the statins intolerant population with results expected in 2014.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|